Entest Biomedical, Inc. Retains Wolfe Axelrod Weinberger Associates LLC as Its Investor Relations Agency

SAN DIEGO, CA--(Marketwire - April 05, 2010) - Entest BioMedical, Inc. (OTCBB: ENTB) announced that it has retained Wolfe Axelrod Weinberger Associates LLC as its investor relations agency effective immediately.

Dr. David Koos, Chairman & CEO of Entest BioMedical, stated, "We've retained Wolfe Axelrod Weinberger Associates to communicate our strategy to the financial community in order to increase investor awareness and thereby improve shareholder value. We believe an active investor relations program will broaden our investor exposure and Wolfe Axelrod Weinberger will provide us with seasoned experience in this area. Wolfe Axelrod Weinberger Associates brings to us thirty years of successful investor relations experience and an extensive network of contacts. We look forward to working closely with Wolfe Axelrod Weinberger to accomplish our primary objective of increasing shareholder value."

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT-576™ is a proprietary laser device currently under development by Entest. The Company has filed 4 patent applications relating to the treatment of COPD. Entest BioMedical Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN). Recently Entest announced publication of its platform technology in the peer-reviewed Journal of Translational Medicine which is available at http://www.translational-medicine.com/content/8/1/16. For additional information on Entest, go to the Company's website: www.entestbio.com or its blog site: www.entestbioblog.com.

Forward-looking statements:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.